Dr. Daniel Emeka Ezekwudo, MD

Dr. Ezekwudo practices at Florida Cancer Specialists & Research Institute - Cape Coral Cay West in Cape Coral, Florida.

Dr. Ezekwudo's NPI, 1942649769, was assigned on June 15, 2013. Dr. Ezekwudo holds Michigan license 4301103358.

Dr. Ezekwudo's primary practice is Florida Cancer Specialists & Research Institute - Cape Coral Cay West, at 1708 Cape Coral W Pkwy, Cape Coral, FL 33914 in Lee County. The practice phone is (239) 541-4633.

Dr. Ezekwudo's primary practice is Florida Cancer Specialists & Research Institute - Cape Coral Cay West in Cape Coral, Florida. Dr. Ezekwudo is also affiliated with Corewell Health William Beaumont University Hospital. The medical group on file is Florida Cancer Specialists & Research Institute. Dmand AI also links Dr. Ezekwudo to 4 more hospitals, 6 medical groups, 2 group practices and clinics and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ezekwudo practices, 8 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Ezekwudo's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Ezekwudo's licenses on file in 3 states: Michigan, Arizona and Louisiana.

CMS data shows 21,612 Medicare services from Dr. Ezekwudo across 26 procedure codes in 2024, for 415 Medicare patients. Medicare paid $194,024 for them.

CMS counts 415 Medicare patients who saw Dr. Ezekwudo in 2024. The largest group is 65 to 74, with 173 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 20% are also on Medicaid. Their average risk score is 2.74, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ezekwudo's median patient age at 73, with 55% women.

In 2024, Dr. Ezekwudo wrote 383 Medicare Part D claims for 105 patients. 85% of them were for generic drugs. CMS names the drug for 218 of them, across 9 drugs with 11 or more claims each, at $29,525 in total drug cost. In 2023, CMS named 299 claims across 13 drugs.

Dr. Ezekwudo accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 20 papers to Dr. Ezekwudo, published from 2017 to 2025. 2024 was the busiest year, with 6. The most frequent topics are Biomarkers, Tumor. Dr. Ezekwudo has published most often in Cureus. Dr. Ezekwudo's most frequent co-authors are Bolanle Mariam Gbadamosi, MD, Martin Tobi, MD and Mohammad Muhsin Chisti, MD.

CMS Open Payments shows 176 general payments to Dr. Ezekwudo from 52 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 65% of the total. Novartis Pharmaceuticals Corporation paid the most, $1,822.